Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Interventional × GDC-0084 × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 340 Cyclophosphamide 332 Carboplatin 267 Gemcitabine 243 Paclitaxel 238 Nivolumab 227 Cisplatin 208 Radiotherapy 187 Bevacizumab 174 Dexamethasone 163 fludarabine 162 Docetaxel 161 Rituximab 153 Capecitabine 143 Oxaliplatin 130 Lenalidomide 129 Fluorouracil 124 Temozolomide 118 Cytarabine 114 Irinotecan 111 Cetuximab 109 Etoposide 108 venetoclax 104 fludarabine phosphate 104 Injections 96 Doxorubicin 96 130-nm albumin-bound paclitaxel 96 Azacitidine 93 Ipilimumab 92 Pemetrexed 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07391215 2026-02-05

5G-PEARL

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡